MS Pharma Announces Strategic Growth Investment from Olayan Financing Company

MS Pharma, a prominent pharmaceutical company based in Jordan, has announced a minority equity investment from Olayan Financing Company (OFC) aimed at bolstering its growth trajectory in Saudi Arabia and the broader MENA region. The deal, finalized on May 18, 2026, involves the issuance of new share capital by MS Pharma in exchange for a substantial cash investment from OFC, though the specific deal value remains undisclosed. This partnership is expected to enhance MS Pharma's financial position and support its strategic initiatives, particularly in the expansion of its biosimilars portfolio and manufacturing capabilities.

Founded in 1947, Olayan Financing Company is a leading multinational enterprise with a diverse investment portfolio spanning various sectors, including public and private equities, real estate, and strategic partnerships. The company has a strong presence in Saudi Arabia and across the MENA region, making it a valuable partner for MS Pharma as it seeks to deepen its market penetration. The investment aligns with OFC's long-term investment philosophy, which emphasizes sustainable growth and value creation in the companies it partners with.

The collaboration is particularly timely as MS Pharma aims to capitalize on the growing demand for biologics and biosimilars in the MENA region. With its biologics manufacturing facility recently receiving SFDA GMP approval, MS Pharma is positioned to become a key player in the local biologics market, with plans to be the first supplier of locally manufactured biologics in Saudi Arabia. This investment from OFC is expected to provide the necessary resources to accelerate these initiatives, enhancing MS Pharma's ability to deliver high-quality, affordable medicines to patients and healthcare providers.

Strategically, the partnership will also enable MS Pharma to strengthen its supply chain resilience and expand its collaboration with global development and licensing partners. By leveraging OFC's established network and operational expertise, MS Pharma can enhance its manufacturing capabilities and explore new market opportunities, thereby reinforcing its commitment to the Saudi National Biotechnology Strategy and Vision 2030.

The broader implications of this investment reflect a growing trend in the pharmaceutical sector towards consolidation and strategic partnerships aimed at enhancing operational efficiencies and market reach. As companies like MS Pharma and OFC collaborate to navigate the complexities of the MENA pharmaceutical landscape, the focus on innovation and localized production is likely to drive further investment in the region. This partnership not only underscores the potential for growth within the pharmaceutical industry but also highlights the importance of strategic alliances in achieving long-term success in a competitive market.